Hosted on MSN1mon
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The study evaluated two different doses of Lumakras (960 mg daily or 240 mg daily) in combination with Vectibix versus the investigator's choice of SOC (trifluridine and tipiracil or regorafenib ...
Hosted on MSN1mon
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...
pharmaphorum2y
Phase 3 trial confirms Lumakras role in lung cancer
Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for its ...
pharmaphorum4d
ESMO: Amgen reveals Lumakras data as rival looms in rear-view mirror
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...
Nasdaq1mon
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
The study compared Lumakras at doses of 960 mg and 240 mg in combination with Vectibix to investigator's choice of standard of care of trifluridine/tipiracil or regorafenib. The biotechnology ...
Cure Today1mon
Explaining KRAS Mutations For Patients With Colorectal Cancer
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...